

# NMSGROUP

## ONCOLOGY FORWARD

**NERVIANO  
MEDICAL  
SCIENCES**

**ACCELERA**

**NERPHARMA**

**SIMIS**

### FOR IMMEDIATE RELEASE

Sidney Dung  
+39 0331 511380  
Sidney.dung@nmsgroup.it

### **NMS Group wins China Awards for creating concrete values**

Nerviano, 9 February 2021 – NMS Group has been named the winner of the “Value creators’ category at the prestigious ‘China Awards 2021’ during the online event held by the Italy China Foundation on Monday 8 February 2021. The “Value creators’ award is a recognition for companies in Italy that have successfully implemented concrete projects aiming at the Chinese market and delivered the best result. The China Awards, now already in its fifteenth annual edition, is a ceremonial event organized by the Italy China Foundation with the aim to communicate the importance and benefits of international collaborations between Italian and Chinese companies and share the success stories.



NMS Group, an innovative oncology drug R&D company with more than 400 staffs in Italy, has more than 50 years of history in successfully improving patients’ lives with innovative therapies. It has been collaborating with numerous institutions in China and the relationships have further strengthened since 2018, when Hefei SARI V-Capital Management Co. Ltd., a leading Chinese biotech investment company acquired 90% of NMS Group.

Andrea Agazzi, Chairman of NMS Group commented “*We are absolutely delighted to have won this award, which is a real honor to receive. The China Award has confirmed our continuing efforts in combining the talent, innovation and entrepreneurial spirit for which both Italians and Chinese are renowned. Together with our investors, colleagues, partners and clients in China, we work collaboratively together with a common goal – leveraging the heritage and experience in Italy and the technology and market potential in China to bring molecules that would benefit all. With our PARP inhibitor’s approval in China we have certainly reached a milestone and set up an example for a win-win partnership in our sector.*”

NMS’s winning project as “Value creators” is the approval of a phase I clinical study for its PARP inhibitor (NMS-03305293) by China National Medical Products Administration(NMPA) in December 2020. NMS-03305293, a second-generation PARP inhibitor with differential preclinical pharmacological properties will be trialed in Chinese patients with advanced/metastatic solid tumors to observe its safety and activity in relevant cancer patients.

Nanding Zhao, CEO of NMS Group commented “*This is the first time that one of our drug candidates obtained the NMPA approval for clinical trial in China. We thank the Foundation for recognizing the joint efforts and great collaboration between the NMS Group team in Italy and our partner in China. This award has certainly raised our level of pride and satisfaction and encourage us further to bring the project to the next level. The approval is just the beginning of a path to reach the final product. We look forward to bring more innovative clinical candidates to benefit many cancer patients in Italy, China and the rest of the world soon.*”

###

# NMSGROUP

## ONCOLOGY FORWARD

**NERVIANO  
MEDICAL  
SCIENCES**

**ACCELERERA**

**NERPHARMA**

**SIMIS**

### About NMS Group

NMS Group is Italy's largest innovative oncological R&D based pharmaceutical company. With more than 400 employees of which more than half are highly educated researchers dedicated to groundbreaking research and development. The NMS kinase inhibitor discovery platform as well as the antibody-conjugated payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Entrectinib, discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now member of the Roche Group, who gained recent approvals for commercialization in all major markets. This is a further evidence of the value and competitiveness of the drug discovery platform at NMS Group.

The NMS Group has three subsidiaries: the first, NMS s.r.l. is a FIC / BIC focused, expert drug research and development company, with a robust pipeline of more than a dozen anti-cancer programs ongoing, three of which currently in early clinical stage of development. The other two subsidiaries Accelerera and NerPharMa provide preclinical research services, and CDMO services respectively for local and international customers.

###